BioVentrix raised $14.5 million in a new round of equity financing according to an SEC filing posted this week.
Funds in the round came from 152 unnamed investors, with the 1st sale marked on July 21, 2016, according to the filing. The company is not seeking anymore funds the round.
The company raised the money through the sale of equity and convertible notes, according to the filing.
A total of $1.2 million were provided as sales commissions, with the placement agent also receiving warrants to purchase common stock equal to 10% of the number of shares offered in the round at an exercise price of $7.50 per share, according to the filing. Sales compensations were paid to Huntington, N.Y.’s Taglich Brothers.
In May, BioVentrix said its Revivent TC transcatheter ventricular enhancement system saw its 1st clinical use in treating ischemic cardiomyopathy at Berlin, Germany’s Deutsches Herzzentrum.
The device was used by interventional cardiologist Dr. Cristoph Klein and Dr. Felix Hennig, with assistance from Dr. Sebastian Kelle, according to BioVentrix.